Revolution Medicines, Inc. Warrant Share Price
RVMDWRevolution Medicines, Inc. Warrant Stock Performance
Open $1.73 | Prev. Close $1.56 | Circuit Range N/A |
Day Range $1.73 - $1.73 | Year Range $0.03 - $3.43 | Volume 100 |
Average Traded $1.73 |
Revolution Medicines, Inc. Warrant Share Price Chart
About Revolution Medicines, Inc. Warrant
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Revolution Medicines, Inc. Warrant Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
12-Feb-26 | $1.73 | $1.61 | +0.00% |
12-Feb-26 | $1.73 | $1.61 | +6.62% |
09-Feb-26 | $1.51 | $1.51 | +7.47% |
02-Feb-26 | $1.41 | $1.41 | -8.17% |
30-Jan-26 | $1.61 | $1.53 | -4.38% |
29-Jan-26 | $1.76 | $1.60 | -5.88% |
28-Jan-26 | $1.79 | $1.70 | -10.53% |